SC 13G 1 tm249746d1_sc13g.htm SC 13G

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No. ________)*

 

MERUS N.V.

(Name of Issuer)

 

Common Shares, nominal value €0.09 per share

(Title of Class of Securities)

 

N5749R100

(CUSIP Number)

 

March 25, 2024

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨  Rule 13d-1(b)
x  Rule 13d-1(c)
¨  Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. N5749R10013GPage 2 of 5 Pages

 

1.  

NAMES OF REPORTING PERSONS

 

Incyte Corporation

   
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨
   
3.   SEC USE ONLY
 
   
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
   

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
  5.   SOLE VOTING POWER
 
4,004,544
  6.   SHARED VOTING POWER
 
0
  7.   SOLE DISPOSITIVE POWER
 
4,004,544*
  8.   SHARED DISPOSITIVE POWER
 
0

9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,004,544

   
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨
 
   
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

6.9%*

   
12.  

TYPE OF REPORTING PERSON (see instructions)

 

CO

   

 

*See footnotes to Item 4 below.

 

 

 

 

CUSIP No. N5749R10013GPage 3 of 5 Pages

 

Item 1(a) Name of Issuer:
   
  Merus N.V. (“Merus”)
   
Item 1(b) Address of Issuer’s Principal Executive Offices:
   
  Uppsalalaan 17, 3584 CT Utrecht, The Netherlands
   
Item 2(a) Name of Person Filing:
   
  Incyte Corporation (“Incyte”)
   
Item 2(b) Address of the Principal Business Office or, if none, Residence:
   
  1801 Augustine Cut-Off, Wilmington, DE 19803
   
Item 2(c) Citizenship:
   
  Delaware
   
Item 2(d) Title of Class of Securities:
   
  common shares, nominal value €0.09 per share (“Common Shares”)
   
Item 2(e) CUSIP Number:
   
  N5749R100
   
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
   
  Not applicable
   
Item 4. Ownership
   
  (a) Amount beneficially owned: 4,004,544 shares
   
  (b) Percent of class: 6.9%(1)
   
  (c) Number of shares as to which the person has: 
   
    (i) Sole power to vote or to direct the vote: 4,004,544 shares
   
    (ii) Shared power to vote or to direct the vote: 0
   
    (iii) Sole power to dispose or to direct the disposition of:  4,004,544 shares (2)
   
    (iv) Shared power to dispose or to direct the disposition of: 0

 

 

 

 

CUSIP No. N5749R10013GPage 4 of 5 Pages

 

(1)The ownership percentage of Incyte has been calculated based on a total of 57,878,284 Common Shares outstanding as of February 22, 2024, as disclosed by Merus in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2024.

 

(2)Incyte has reevaluated its investment in Merus and, in addition to no longer holding the Common Shares reported in this Schedule 13G (the “Shares”) with a purpose or effect of changing or influencing control of Merus or in connection with or as a participant in any transaction having that purpose or effect, Incyte expects to make sales of the Shares over time as market conditions permit in the open market or in private transactions. Incyte may, however, decide to discontinue any such sales or make purchases of Common Shares in the future either in the open market or in private transactions depending on various factors, including, among other things, Incyte’s evaluation of the market for the Common Shares, stock market and general economic conditions, Merus’s business, prospects and financial condition, other opportunities available to Incyte, and other future developments.

 

Item 5.Ownership of Five Percent or Less of a Class.

 

Not applicable

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable

 

Item 8.Identification and Classification of Members of the Group.

 

Not applicable

 

Item 9.Notice of Dissolution of Group.

 

Not applicable

 

Item 10.Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

 

 

 

CUSIP No. N5749R10013GPage 5 of 5 Pages

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: March 25, 2024

 

  INCYTE CORPORATION
     
  By: /s/ Sheila A. Denton
    Sheila A. Denton
    Executive Vice President and General Counsel